These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 29957272)

  • 1. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De-escalation therapy among bacteraemic patients with community-acquired pneumonia.
    Carugati M; Franzetti F; Wiemken T; Kelley RR; Peyrani P; Blasi F; Ramirez J; Aliberti S
    Clin Microbiol Infect; 2015 Oct; 21(10):936.e11-8. PubMed ID: 26115864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
    Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
    J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
    Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.
    Bordón J; Peyrani P; Brock GN; Blasi F; Rello J; File T; Ramirez J;
    Chest; 2008 Mar; 133(3):618-24. PubMed ID: 18198264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia.
    Cilloniz C; Albert RK; Liapikou A; Gabarrus A; Rangel E; Bello S; Marco F; Mensa J; Torres A
    Am J Respir Crit Care Med; 2015 Jun; 191(11):1265-72. PubMed ID: 25807239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
    Loh LC; Quah SY; Khoo SK; Vijayasingham P; Thayaparan T
    Respirology; 2005 Jun; 10(3):371-7. PubMed ID: 15955152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
    Arnold FW; Wiemken TL; Peyrani P; Ramirez JA; Brock GN;
    Respir Med; 2013 Jul; 107(7):1101-11. PubMed ID: 23660396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.